GE HealthCare Technologies Inc. $GEHC Stock Position Decreased by Klingman & Associates LLC

Klingman & Associates LLC cut its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 32.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,495 shares of the company’s stock after selling 1,716 shares during the quarter. Klingman & Associates LLC’s holdings in GE HealthCare Technologies were worth $259,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of GEHC. JPMorgan Chase & Co. boosted its stake in shares of GE HealthCare Technologies by 49.9% during the 1st quarter. JPMorgan Chase & Co. now owns 5,140,549 shares of the company’s stock worth $414,894,000 after acquiring an additional 1,711,963 shares in the last quarter. Nuveen LLC purchased a new stake in shares of GE HealthCare Technologies in the first quarter valued at $77,058,000. Eminence Capital LP lifted its holdings in shares of GE HealthCare Technologies by 38.7% in the first quarter. Eminence Capital LP now owns 1,819,129 shares of the company’s stock valued at $146,822,000 after purchasing an additional 507,101 shares in the last quarter. Homestead Advisers Corp lifted its holdings in shares of GE HealthCare Technologies by 92.7% in the first quarter. Homestead Advisers Corp now owns 988,600 shares of the company’s stock valued at $79,790,000 after purchasing an additional 475,500 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its holdings in shares of GE HealthCare Technologies by 15.2% in the first quarter. Canada Pension Plan Investment Board now owns 3,111,398 shares of the company’s stock valued at $251,121,000 after purchasing an additional 409,636 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

GE HealthCare Technologies Price Performance

Shares of NASDAQ:GEHC opened at $76.10 on Wednesday. GE HealthCare Technologies Inc. has a 1 year low of $57.65 and a 1 year high of $94.80. The business has a fifty day simple moving average of $74.60 and a 200 day simple moving average of $72.16. The company has a current ratio of 1.16, a quick ratio of 0.93 and a debt-to-equity ratio of 0.85. The firm has a market cap of $34.74 billion, a price-to-earnings ratio of 15.59, a P/E/G ratio of 2.88 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.15. GE HealthCare Technologies had a return on equity of 23.93% and a net margin of 11.22%.The company had revenue of $5 billion for the quarter, compared to analyst estimates of $4.96 billion. During the same period last year, the company earned $1.00 earnings per share. The business’s revenue was up 3.5% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2025 guidance at 4.430-4.630 EPS. As a group, sell-side analysts predict that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Shareholders of record on Friday, October 24th will be issued a dividend of $0.035 per share. This represents a $0.14 annualized dividend and a yield of 0.2%. The ex-dividend date is Friday, October 24th. GE HealthCare Technologies’s dividend payout ratio (DPR) is 2.87%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on GEHC. Barclays began coverage on GE HealthCare Technologies in a report on Monday, October 13th. They issued an “equal weight” rating and a $86.00 target price for the company. BTIG Research increased their target price on GE HealthCare Technologies from $87.00 to $89.00 and gave the company a “buy” rating in a report on Monday, October 13th. Wall Street Zen lowered GE HealthCare Technologies from a “buy” rating to a “hold” rating in a report on Saturday, September 20th. Morgan Stanley set a $74.00 target price on GE HealthCare Technologies in a report on Thursday, September 18th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of GE HealthCare Technologies in a report on Tuesday, October 14th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $85.20.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.